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Abstract
Background: The lack of effective treatments for gliomas makes them a significant health problem and highlights
the need for the development of novel and innovative treatment approaches. Immunotherapy is an appealing
strategy because of the potential ability for immune cells to traffic to and destroy infiltrating tumor cells. However,
the absence of well-characterized, highly immunogenic tumor-rejection antigens (TRA) in gliomas has limited the
implementation of targeted immune-based therapies.
Methods: We hypothesized that treatment with the demethylating agent, decitabine, would upregulate the
expression of TRA on tumor cells, thereby facilitating enhanced surveillance by TRA-specific T cells.
Results and Discussion: Treatment of human glioma cells with decitabine increased the expression of NY-ESO-1
and other well characterized cancer testes antigens. The upregulation of NY-ESO-1 made these tumors susceptible
to NY-ESO-1-specific T-cell recognition and lysis. Interestingly, decitabine treatment of T98 glioma cells also
sensitized them to Fas-dependent apoptosis with an agonistic antibody, while a Fas blocking antibody could
largely prevent the enhanced functional recognition by NY-ESO-1 specific T cells. Thus, decitabine treatment
transformed a non-immunogenic glioma cell into an immunogenic target that was efficiently recognized by NY-
ESO-1–specific T cells.
Conclusions: Such data supports the hypothesis that agents which alter epigenetic cellular processes may
“immunosensitize” tumor cells to tumor-specific T cell-mediated lysis.
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Background
Glioblastoma is the most malignant of the glial tumors.
Patients with glioblastoma have a 5-year survival rate of
less than 3.3% despite advances in surgery, radiation,
and chemotherapeutic techniques [1-3]. Immunotherapy
is a promising new treatment strategy for brain tumors
that may allow for stimulation of an antitumor immune
response while sparing normal brain structures [4,5].
However, gliomas lack well defined TRA for immune
targeting by CD8
+ T-cell effectors.
Cancer testis antigens (CTAs) are expressed in a vari-
ety of tumors, but not in non-neoplastic normal human
cells, with the exception of germ cells [6,7]. NY-ESO-1,
a member of the cancer/testis antigen family, is consid-
ered to be one of the most immunogenic TRAs and
therefore a promising target for cell mediated immunity
[8-13]. NY-ESO-1 expression has been identified at the
protein level in a variety of malignant neoplasms such
as lung cancers, melanomas, synovial sarcomas, and
bladder cancers [11,13-15]. Previous studies, however,
have demonstrated low levels of NY-ESO-1 detected at
the mRNA level in brain tumors [14,16]. Recent evi-
dence has suggested that compounds that influence
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CTAs [17,18]. This increase in gene expression appears
to increase the antigenicity of CTA in some cancers,
such as gliomas, myeloid leukemia and renal cell carci-
noma [19-23].
Decitabine (5-aza-2’-deoxycytidine) is a cytosine analo-
gue that incorporates itself into the DNA strands of pro-
liferating cells [24-26]. It effectively inhibits DNA
methylation and increases gene expression by covalently
binding to the promoter regions of DNA methyltransfer-
ase [24]. DNA methylation is also critically involved in
embryonic development, transcription, chromatin struc-
ture, X-chromosome inactivation, genomic imprinting,
and chromosome stability [27,28]. Aberrant hypermethy-
lation represses transcription by way of CpG islands in
the promoter region and is associated with gene inacti-
vation. Use of decitabine induces re-expression of cer-
tain genes that are otherwise repressed in cell culture
[24]. We hypothesized that treatment with decitabine
would up-regulate the expression of CTAs in gliomas,
thereby sensitizing human glioma cells to immune-
based therapies without having similar effects upon nor-
mal cells.
A recent study provided the first evidence in a glioma
model that decitabine treatment could increase the
expression of NY-ESO-1 and other CTA [21]. In this
study, we analyzed the expression of NY-ESO-1 in 5
established human glioma cell lines and 4 primary
glioma cell lines. We demonstrated that their treatment
with decitabine up-regulated the expression of NY-ESO-
1 and MHC I class, and as a result, induced simulta-
neous release of T cell effector pro-inflammatory cyto-
kines and tumor cell killing. These results suggest that
treatment with decitabine not only increases the expres-
sion of an immunogenic CTA, but can also re-establish
functionality of the apoptotic signaling system within
tumor cells and sensitize these cells to immune-
mediated cell death via the Fas/Fas Ligand pathway.
Methods
Cell lines and human brain tissue samples
Five cell lines, DBTRG05-MG, SNB-19, U-251MG, U-
373MG and T98G derived human glioblastoma cell
lines were kindly provided by Dr. Carol Kruse (UCLA
Department of Neurosurgery, Los Angeles, CA). They
were maintained in DMEM (Mediatech, Inc., Herndon,
Virginia) supplemented with 10% FBS (Gemini Bio-Pro-
ducts, West Sacramento, California), 1% (v/v) penicillin,
streptomycin, and amphotericin B (Mediatech Cellgro,
Manassas, Virginia) and kept in an atmosphere of 5%
CO2 at 37°C. Normal human astrocytes (NHA) were
kindly provided by Dr. Russ Pieper (UCSF Department
of Neurosurgery, San Francisco, CA). A melanoma cell
line, 624.38, was kindly provided by Dr. Steve Rosenberg
(NIH/NCI). Both NHA and 624.38 cells were placed
into identical culture conditions to glioblastoma cell
lines.
Primary tumor cell cultures were derived from four
patients with glioblastomas who had undergone surgical
resection at the UCLA Medical Center. These tissues
were cultured by digesting homogenized tumors in a
collagenase DNAse mixture overnight as previously
described [5,29]. The digested tumor samples were fil-
tered through a mesh and the cells placed into complete
medium as described earlier. The cells were incubated
in 5% CO2 at 37°C. Human brain tissue samples were
also obtained from patients who had undergone resec-
tion at the UCLA Medical Center, CA. All patients pro-
vided written informed consent for these procedures.
Peripheral blood was obtained from healthy human
volunteers provided by the Division of Hematology and
Oncology at UCLA Medical Center, Los Angeles. Per-
ipheral blood mononuclear cells (PBMC) were isolated
by Ficoll gradient centrifugation as previously described
[5]. Written informed consent and institutional IRB
approval was obtained for all studies involving human
bloods and tissues.
Reagent
Decitabine (5-aza-2’-deoxycytidine) was generously sup-
plied by Eisai Pharmaceuticals (Woodcliff Lake, New
Jersey). A 10 μM stock solution of it in DMSO was
stored at -80°C.
In vitro treatment of cultured cells with decitabine
Cells were plated overnight at 10
6cells/ml at 37°C in a
5% CO2 incubator. The following day, the cell culture
medium was replaced with either fresh medium or that
supplemented with 1 μM decitabine. The cells were
treated again the following day in new cell culture med-
ium. At the end of treatment, the medium was replaced
with fresh medium without decitabine, and the cells
were cultured for an additional 48 hours before utilized
in subsequent assays.
Conventional reverse transcription PCR analysis of NY-
ESO-1 expression
Total RNA was isolated with the RNeasy Mini kit (Qia-
gen, Valencia, California) according to manufacturer’s
protocol. 3 × 10
6 human glioblastoma cancer cell lines
or 25 mg of tumor tissue samples were used. cDNA was
synthesized from 1 μg total RNA by using Omniscript
Reverse Transcription kit (Qiagen), again according to
the manufacturer’s protocol. PCR was facilitated by
using the Accuprime GC-rich kit (Invitrogen, Carlsbad,
California). In each PCR, 2 μlc D N Aw a su s e di na3 5 -
μl reaction volume containing 10 μMs e n s ea n da n t i -
sense primers, 5 μL 5× PCR buffer (A for GC-rich
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DNA target), and 1 μl of Accuprime GC-Rich DNA
polymerase (Invitrogen). The PCR primers were as fol-
lows: NY-ESO-1 forward primer: 5’-CATCACGGATC-
CATGCAGGCCGAAGGCCGG-3’, reverse primer: 5’-
ACCCGGGGTACCGCGCCTCTGCCCTGAGGG-3’,
GAPDH forward primer: 5’-GAAGGTGAAGGTCG-
GAGT-3’, reverse primer: 5’-GAAGATGGTGATGG-
GATTTC-3’ (Invitrogen). The PCR cycling parameters
were as follows: denaturation at 95°C for 30 s, primer
annealing at 60°C for 30 s, and 40 cycles of extension at
72°C for 60 s. PCR cycling was preceded by an initial
denaturation at 95°C for 3 min, followed by final exten-
sion at 72°C for 10 min. The PCR products were elec-
t r o p h o r e s e do n1 %a g a r o s eg e l sa n da n a l y z e da f t e r
staining with ethidium bromide. Densitometry analysis
was performed using the QuantityOne program (BioRad,
Hercules, CA).
Quantitative real-time analysis of NY-ESO-1 expression
Quantitative RT-PCR was performed with the LightCy-
cler real-time RT-PCR system (Roche, Mannheim, Ger-
many), using the LightCycler SYBR green mastermix
(Roche). Primers specific for NY-ESO-1 were as follows:
forward primer: 5’-TGTCCGGCAACATACTGACT-3’,
reverse primer: 5’-ACTGCGTGATCCACA TCAAC-3’.
GAPDH forward primer: 5’-AGCCACATCGCTCAGA-
CAC-3’, reverse primer: 5’-CGCCCAATACGAC-
CAAATC-3’ (Invitrogen). Each sample was amplified as
follows: 1 cycle at 95°C for 10 min, 40 cycles at 95°C for
15 s, and 60°C for 1 min. Triplicate samples were tested.
Microarray analysis
Total RNA was extracted from decitabine treated and
untreated U-251 MG cells using the RNeasy mini kit
(Qiagen). cDNA was generated, quantified and hybri-
dized to U133 Plus 2.0 arrays at the UCLA DNA Micro-
array Facility using standard Affymetrix protocols. CEL
files were normalized using GeneSpring GX 11.5.1 soft-
ware (Agilent Technologies) with LiWong. To evaluate
t h eb a s e l i n ee x p r e s s i o no fN Y - E S O - 1i nh e t e r o g e n e o u s
human brain tumor tissues, we analyzed the relative
expression of NY-ESO-1 using microarray gene expres-
sion profiling in over 300 human brain tumor samples.
The relative expression of NY-ESO-1 was normalized
and tested. Dots plotted underneath the black line are
considered to have at or under background relative
expression levels.
FACS analysis and antibodies
Cells (10
5) obtained from decitabine-treated and
untreated U-251 MG cells were used for flow cytometric
analysis. Cells were washed twice with FACS staining
buffer and stained with antibodies to HLA-A, B, C
(clone DX17) and HLA-A2 (clone BB7.2) (BD Pharmin-
gen, San Diego, California). A Becton Dickinson LSRII
was used for acquisition and the acquired data were
analyzed using FlowJo (TreeStar, Ashland, Oregon).
Gates were set based on singly-stained isotype-control
antibodies (data not shown).
Generation and maintenance NY-ESO-1 TCR-transduced
lymphocytes
Six well cluster plates were coated with Retronectin
(RN) (Takara, Madison, Wisconsin) at a concentration
of 10 μg/ml overnight at 4°C. The next day, blocking
buffer (PBS containing 2% Human Serum Albumin) was
added for 30 min and washed. Supernates were retrieved
from a stable PG13-based retroviral producer cell line
encoding a HLA-A*0201-restricted NY-ESO157-165 speci-
fic T cell receptor (TCR) generated in the MSGV1 ret-
roviral vector backbone, as described [30]. The PG13-
based NY-ESO-1 stable retroviral packaging cell line
was obtained from Dr. Paul Robbins (Surgery Branch,
NCI/NIH). Anti-CD3 (clone OKT-3; 50 ng/ml) was
used to stimulate human PBMCs for 48 hours in X-
VIVO 15 medium supplemented with 5% human AB
serum in the presence of 300 IU IL-2/ml prior to spin-
infection. Stimulated PBMCs were transduced twice as
described [15,30]. Transduced T cells were maintained
in X-VIVO 15 medium supplemented 5% human AB
serum and 300 IU IL-2/ml. The cells were expanded for
3 days in the presence of IL-2 and then rested for 2
days in the absence of IL-2.
Transduction efficiency was evaluated 48 hr post-
transduction by NY-ESO-1 T cell receptor staining of
the CD3
+CD8
+ gated population using antihuman anti-
bodies to CD3-PerCP (clone SK7; BD Biosciences, San
Diego, CA), CD8-FITC (clone SFCI21Thy2D3; Beckman
Coulter, Brea, CA), and TCR Vb13.1-PE (clone IMMU
222; Beckman Coulter). Detection of the NY-ESO-1
peptide-MHC complex was accomplished by NY-ESO-1
tetramer staining as described [31].
CD107A marker staining of NY-ESO-1 TCR transduced
PBMC after co-culture with human glioma cells
NY-ESO-1 TCR-transduced PBMCs and untransduced
PBMCs were harvested and resuspended at a concentra-
tion of 1 × 10
7 cells/ml. Treated and untreated HLA-
0201
+ T98G glioma cells were harvested using trypsin
and reconstituted to 1 × 10
7 cells/ml. 1 × 10
6 PBMCs
were co-incubated with target T98G cells in 96-well
round-bottomed plates at a 1:1 ratio with total medium
volume of 200 μl. Golgi plug (1×) and 5 μlo fC D 1 0 7 A -
AF647 (clone H4A3) (BD Biosciences) were added into
each well and incubated for 6 hr at 37°C. Cells were
washed twice with FACS staining buffer (PBS + 2% FBS)
and stained with surface antibodies to CD4-PE (clone
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BD Biosciences), and CD3-PE-Cy5 (clone UCHT1; BD
Biosciences) on ice for 25 min. Cells were washed, fixed
with Fixation Buffer (eBioscience, San Diego, CA), and
kept at 4°C until analysis. Data were collected using a
Becton Dickinson LSRII and analyzed with FlowJo soft-
ware (TreeStar).
ELISA and Cytokine Bead Array
To determine cytokine concentrations, supernates were
collected from the Golgi-plug free overnight co-cul-
tures. Cell-free supernates were analyzed for inter-
feron-g using an ELISA kit (eBiosciences) or for
simultaneous levels of IFN-g,T N F - a,I L - 2 ,I L - 4 ,I L - 5 ,
and IL-10 using a cytokine bead array (CBA) system
(BD Biosciences), following the manufacturer’si n s t r u c -
tions. Co-cultures at 1:1 (E:T) ratios were placed into
complete medium (X-VIVO 15 with 5% human AB
serum) in 96-well round-bottomed plates and incu-
bated overnight at 37°C. All samples were in triplicate
and supernates were harvested for cytokine detection.
IFN-g ELISAs were performed according to the manu-
facturer’s specification (ELISA Ready-set-go,
eBioscience). Color development was stopped after 2-5
minutes. The colorimetric density of each well was
measured at 450 nm by a plate reader, and the final
concentration of each sample was calculated (pg/ml)
based on the standard curve. Triplicate assays were
performed for each case and the results were expressed
as the mean of 3 separate assays.
Data acquisition for CBA experiments was performed
with the FCAP Array software (BD). Once the FCAP
Array experiment was created, the files were exported to
the BD FACSArray software for sample acquisition and
analysis following manufacturer’s protocol.
Apoptosis studies
Apoptosis was induced in T98G glioma cells or 624.38
melanoma cells by the addition of an agonistic anti-
CD95 antibody (clone CH-11; Medical and Biological
Laboratories). Cells were analyzed for Fas-expression
using a CD95-PE mAb (clone DX2) (BD Pharmigen).
On the day of harvest, the target cells were cultured in
DMEM with FBS containing 200 ng/ml of CH-11 for 24
hr. Cells were washed and resuspended in 1× binding
buffer (Invitrogen). Cells were then stained with FITC-
conjugated Annexin V (Invitrogen) and the vital dye,
propidium iodide (PI, Invitrogen), for 20 min at 37°C.
Cells negative for both PI and Annexin V staining were
considered live cells; early apoptotic cells were PI-nega-
tive, Annexin V-positive; and late apoptotic/dead cells
were PI-positive, Annexin V-positive. Each specimen
was analyzed in triplicate, and the results shown were
the mean ± SE of 3 assays.
Mixed lymphocyte tumor cell cultures stimulated with
antagonistic Fas mAb
PBMCs transduced with the NY-ESO-1 TCR were co-
cultured with tumor target cells and blocked with an
antagonistic anti-CD95 antibodies (clone ZB4; Medical
and Biological Laboratories). Treated and untreated
HLA-0201
+ T98G glioma cells were harvested using tryp-
sin and reconstituted to 4 × 10
5 cells/ml and blocked
with antagonistic anti-CD95 antibodies for 1 hr on ice.
Cells were washed and reconstituted to 1 × 10
7 cells/ml
in complete medium. Transduced PBMCs were plated
with target cells in 96-well round-bottomed plates at a
1:1 ratio with total medium volume of 200 μl. Golgi plug
(1×) and 5 μl of CD107A-AF647 (clone H4A3) (BD Bios-
ciences) were added into each well and incubated for 6
hr at 37°C. Cells were washed twice with FACS staining
buffer and stained with surface antibodies to CD4-PE,
CD8-PacBlue, and CD3-PE-Cy5 on ice for 25 min. Cells
were fixed with Fixation Buffer and kept at 4°C until ana-
lysis. Data were collected using a Becton Dickinson LSRII
and analyzed using FlowJo software (TreeStar).
Statistical analysis
Continuous variables were compared using a paired Stu-
dent’s t-test. Results comparing more than two groups
were analyzed by ANOVA followed by Kruskal-Wallis
statistics. Values were considered significant at P < 0.05.
Resulting data files from the gene expression profiling
experiments were analyzed using RMA from BIOcon-
ductor. All statistical analysis and graphs were con-
structed using GraphPad software.
Results
Decitabine increases MHC I and CTA expression
We previously demonstrated that many melanoma asso-
ciated antigens (MAA) are expressed by glioma cells,
but at distinctly lower levels compared with melanoma
cells [32]. To identify epigenetically silenced genes in
glioma cells, we treated cells with the DNA methyltrans-
ferase inhibitor, decitabine, and then performed global
gene expression profiling. Many CTA and major histo-
compatibility complex (MHC class I) antigens can exhi-
bit methylation in their promoters, thus influencing
their protein expression at an epigenetic level. As shown
in Figure 1A, an unbiased microarray screening ranked
a significant number of CTA as being highly up-regu-
lated after decitabine treatment. These data included a
58-376 fold increase in NY-ESO-1 and other related
CTA (Table 1). Multiple genes from the MHC and
death receptor family were also upregulated (Additional
File 1). To confirm changes in the protein expression of
MHC, we stained cells with monoclonal antibodies to
pan class I (HLA-A, B, C) as well as to HLA-A2 specifi-
cally. Decitabine treatment resulted in increased surface
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(Figure 1B).
Decitabine increases the expression of NY-ESO-1 on
established glioma cells and primary glioblastoma cells
obtained from surgical resection
To confirm our microarray results, conventional RT-PCR
and quantitative RT-PCR were used to assess NY-ESO-1
expression in established glioma cell lines and primary
glioblastoma cell explants placed into culture immediately
after surgical resection (Figure 2). Multiple glioma cell
lines allowed us to assess whether the induction of NY-
ESO-1 expression was a consistent feature of decitabine
treatment. Results showed a uniform up-regulation of NY-
ESO-1 in all decitabine-treated cell lines, with some varia-
tion in levels of expression (Figure 2A). Decitabine-treated
A
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Figure 1 Treatment of human glioma with decitabine up-regulates cancer-testes antigens and MHC I. A) Total RNA was isolated from U-
251MG glioma cells treated with decitabine or vehicle control and subjected to global gene expression classification using Affymetrix human
U133 Plus 2.0 microarray chips. B) Decitabine-treated and untreated U-251MG glioma cells were stained with a-HLA-A, B, C and a-HLA-A2.
Representative flow cytometric analysis data are shown here. Similar results were seen in two independent experiments.
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Page 5 of 13primary cell lines also showed uniform up-regulation of
NY-ESO-1 expression (Figure 2B). However, such up-reg-
ulation of NY-ESO-1 did not occur in non-malignant, nor-
mal human astrocytes (NHA), alleviating potential
concerns that systemic administration of decitabine will
up-regulate CTA on normal brain cells (Figure 2C). An
NY-ESO-1
+HLA-0201
+ melanoma cell line (624.38) was
used as a positive control. The high endogenous expres-
sion of NY-ESO-1 was not changed with decitabine treat-
ment (Figure 2C). To quantify the induction of NY-ESO-1
after decitabine treatment, real-time PCR was performed,
which correlated with the results obtained with
Table 1
Gene Symbol Gene Title Fold Induction
PRAME Preferentially expressed antigen in melanoma 1.01
MAGE-A1 Melanoma antigen Family -A1 1.39
MAGE-B2 Melanoma antigen Family-B2 92.92
CTAG1A///CTAG1B Cancer/testis antigen 1A/1B (NY-ESO-1) 376.59
MAGE-A9 Melanoma antigen Family-A9 83.45
MAGE-A4 Melanoma antigen Family-A4 248.02
CTAG1A///CTAG1B Cancer/testis antigen 1A/1B (LAGE-2, NY-ESO-1) 57.90
CTAG2 Cancer/testis antigen-2 (LAGE-1, CAMEL) 654.87
MLANA Melan-A/MART-1 1.86
TYR Tyrosinase (oculocutaneous albinism 1A) 0.82
DCT Dopachrome tautomerase (TRP-2) 0.94
MAGE-C1 Melanoma antigen Family-C1 7.03
AIM-2 Absent in melanoma-2 0.82
SILV Silver homolog (gp100) 0.78
*(log2 of normalized gene expression values)
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Figure 2 Up-regulated expression of NY-ESO-1 in human glioma-derived cell lines and primary cell lines treated with decitabine. A)
Representative data for established glioma cell lines; B) primary glioblastoma cells obtained from surgical resection; or C) normal human
astrocytes (NHA) and a NY-ESO-1
+ human melanoma line, 624.38. Only decitabine-treated glioma cells demonstrated expression of NY-ESO-1. D)
Using SYBR green DNA labeling and quantitative PCR primers specific for NYESO-1 and GAPDH, the cDNA was amplified using a real-time PCR
protocol. The relative fold change in gene expression is graphed showing an increase average fold change in treated T98G and glioblastoma #1
cells compared to untreated (***p=0.0001 and **p=0.007). Similar results were seen in three replicate experiments.
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untreated control cells, the decitabine-treated T98G and
glioblastoma #1 cells showed average log fold increases in
the gene expression of NY-ESO-1 (3155.12 and 544.29,
respectively) both of which were statistically significant (p
= 0.0001 and 0.0075).
To evaluate the baseline expression of NY-ESO-1 in
heterogeneous human brain tumor tissues, a large panel
of normal tissues and brain tumors of varying grades
were subjected to global gene expression profiling using
Affymetrix U133 2.0 chips. NY-ESO-1 was not expressed
in lower-grade gliomas (WHO Grades II-III). However,
significantly elevated expression was detectable in a small
percentage of medulloblastoma and glioblastoma (WHO
Grade IV) tumor specimens. Such expression was com-
parable to the expression of NY-ESO-1 observed in nor-
mal testes, the only non-malignant, postnatal tissue that
normally expresses this CTA (Figure 3). These data clar-
ify the frequency and degree of expression of NY-ESO-1
in heterogeneous patient samples.
Immunosensitization of human glioma after decitabine
treatment
To evaluate whether up-regulated expression of NY-
ESO-1 and MHC I sensitized these tumor cells to T cell
recognition, we expressed an NY-ESO-1 specific T-cell
receptor clone 1G4 in normal human PBMCs utilizing a
retroviral transduction system [30]. Within the trans-
duced CD3
+CD8
+ T-cell population of PBMCs, 56% of
cells expressed TCRVb13.1, a TCR known to be
expressed by the clone 1G4-a95:LY NY-ESO-1 TCR
[30] (Additional File 2). Untransduced cells showed only
small frequencies of a TCRVb13.1
+ T cell population.
Tetramer staining revealed that nearly 50% of the CD3
+CD8
+ population was NY-ESO-1 specific (Figure 4A).
Tetramer staining also showed that approximately 45%
of the CD3
+CD4
+ population was NY-ESO-1 specific.
To evaluate the functional recognition of glioma cells
by NY-ESO-1 specific T cells, the cells were co-cul-
tured and then stained for intracellular expression of
CD107A (LAMP-1). The cell surface mobilization of
CD107A has been directly linked to CTL lytic granule
release and target cell death [33]. In a representative
study that has been repeated at least 3 times, NY-ESO-
1 specific CD8
+ T cells, gated from the CD3
+CD8
+
population, exhibited a 7% or a 68% expression of
CD107A when co-cultured with control or decitabine-
treated T98 glioma cells, respectively (Figure 4B). NY-
ESO-1 specific CD4
+ T cells, gated from the CD3
+CD4
+ population, did not respond to the co-cultures (data
Figure 3 Expression of NY-ESO-1 in human brain tumor tissues. A large panel of normal tissues and brain tumors of varying grades were
subjected to global gene expression profiling using Affymetrix U133 2.0 chips. The relative expression of NY-ESO-1 was normalized and tested.
Dots plotted underneath the black line are considered to have background relative expression levels.
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Page 7 of 13not shown). NY-ESO-1 specific T cells co-cultured
with an HLA-A*0201
+,N Y - E S O - 1
+ melanoma line
(624.38) exhibited a 65% expression of CD107A (data
not shown). To assess the release of cytokines by NY-
ESO-1 specific T cells, we used the cell-free supernates
of overnight co-cultures for ELISA and CBA. As
shown in Figure 5A, significantly elevated concentra-
tions of IFN-g (1133.9 pg/ml) were detected when NY-
ESO-1 specific T cells were co-cultured with decita-
bine-treated T98 glioma cells, whereas, co-culture with
untreated glioma cells was below the level of detection.
Co-culture of untransduced PBMCs with control or
decitabine-treated glioma cells also did not elicit the
release of detectable IFN-g. Using cytometric bead
a r r a y s ,w ew e r ea b l et od e t e c tm u l t i p l eT h 1 / T h 2c y t o -
kines simultaneously secreted by NY-ESO-1 specific T
cells. Significant differences in the concentrations of
IFN-g,T N F - a, and IL-5 were observed only when NY-
ESO-1 specific T cells were co-cultured with decita-
bine-treated T98 glioma cells (Figure 5B; p < 0.0001).
Small differences were also seen with IL-2 and IL-4,
but not IL-10 (data not shown). Thus, treatment of
T98 glioma cells with decitabine results in significantly
enhanced NY-ESO-1 specific T cell recognition and
secretion of Th1-type cytokines along with IL-5.
Decitabine sensitizes cells to immune-mediated cell death
via a Fas/Fas Ligand pathway
To test whether decitabine treatment sensitized glioma
cells to distinct immune-mediated death receptor path-
ways, we assessed expression of TNFR, TRAIL-DR4,
TRAIL-DR5, and Fas on T98 glioma cells by flow cyto-
metric analyses. No changes in the expression of TNFR,
TRAIL-DR4, or TRAIL-DR5 were observed after decita-
bine treatment (data not shown). Small, but detectable
increases in the mean fluorescence intensities (MFI) of
Fas (CD95) were observed after decitabine treatment
(Figure 6A). Furthermore, addition of an agonistic Fas
mAb to human T98 glioma cells enhanced tumor cell
death when pre-treated with decitabine (Figure 6B).
Staining of T98G glioma cells with Annexin V and pro-
pidium iodide (PI) indicated the average percentages of
late apoptotic cells at 17%, 26%, 20%, and 51% in
untreated, untreated with Fas mAb, decitabine-treated
alone, and decitabine-treated with Fas mAb, respectively
(Figure 6B). One-way ANOVA statistical testing showed
a significant difference between the control and Fas-
antibody treated groups (p < 0.01). There was also a sig-
nificant difference observed within untreated and decita-
bine-treated groups with the addition of the agonistic
Fas mAb (*p =0 . 0 2 1 5a n d* * p = 0.0049). Such effects
B
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O
U
N
T
CD107A
=  6.47%
=  6.97%
=  68.15%
Figure 4 Retroviral transduction of PBMC with a cloned NY-ESO-1 specific T cell receptor allows for T cell recognition of decitabine-
treated human T98 glioma cells. Normal donor peripheral blood mononuclear cells (PBMCs) were activated with OKT-3 at a concentration of
50 ng/mL for two days and then harvested for transduction. A) PBMCs were transduced with retroviral constructs encoding a HLA-A*0201-
restricted NY-ESO-1 T cell receptor, and stained with fluorescent mAbs and tetramer NY-ESO-1 percentage. B) Representative flow cytometric
analysis of CD107A of decitabine-treated and untreated T98G glioma cells (solid filled, NY-ESO-1 specific T cells alone; dashed line, NY-ESO-1
specific T cells co-cultured with untreated T98G glioma cells; solid line, NY-ESO-1 specific T cells co-cultured with decitabine-treated T98G glioma
cells). Golgi-plug was added to co-cultures and stained with CD107A before incubation. The lymphocytes were stained with antibodies to CD3,
CD4, and CD8 and subsequently fixed. The experiment was repeated three times with similar findings.
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Page 8 of 13on Fas-mediated apoptosis were consistently observed at
timepoints as early as 4-6 hours and as late as 4 days
(data not shown).
Because decitabine pre-treatment sensitized glioma
cells to Fas mAb mediated cell death with an agonistic
mAb, we also tested whether such death receptor path-
ways were functionally important for NY-ESO-1 specific
T cell recognition and killing of glioma cells. Untreated
T98G glioma cells, blocked with a Fas antagonistic anti-
body, showed no difference in CD107A expression com-
pared to untreated T98G glioma cells co-cultured with
NY-ESO-1 specific T cells (Figure 6C). However, decita-
bine-treated T98G glioma cells, blocked with a Fas
antagonistic antibody, showed dramatic decreases in
CD107A expression levels compared to decitabine-trea-
ted T98G glioma cells co-cultured with NY-ESO-1 spe-
cific T cells (Figure 6D). The NY-ESO-1 specific T cells
alone (negative control) showed minimal release of
CD107A expression. To address the effect of blocking
the Fas pathway on cytokine release, supernatants
derived from NY-ESO-specific T cells co-cultured with
T98G cells were tested in cytokine bead arrays. Addition
of the antagonistic Fas mAb to decitabine-treated cells
largely inhibited the entire induction of Th1-type cyto-
kine release (IFN-g and TNF-a) by NY-ESO-1 specific T
lymphocytes (Figure 6E). IL-10 concentrations appeared
to decrease but were not as prominent as the other
Th1/Th2 cytokines (data not shown). IL-5 concentra-
tions were almost completely inhibited as well.
Discussion
One of the major challenges of developing immunother-
apeutic techniques that target cancer/testis antigens,
such as NY-ESO-1, is their low and variable baseline
expression in solid tumors. We demonstrated that base-
line, untreated glioma cells do not express detectable
levels of NY-ESO-1. However, treatment with 1 μMo f
decitabine for 48 hr significantly induced the expression
of NY-ESO-1 mRNA expression, as shown by conven-
tional and quantitative RT-PCR. Such data confirms the
recent work by Natsume, et al., who demonstrated that
the CTA upregulation was coordinately associated with
decreased promoter methylation [21]. Microarray data
suggest that approximately 2% of glioblastomas express
NY-ESO-1. However, NY-ESO-1 expression can be
induced quickly with decitabine treatment, indicating
epigenetic regulation likely is responsible for the normal
silencing of NY-ESO-1. Increases in NY-ESO-1 expres-
sion resulted in NY-ESO-1 specific T cell recognition
and killing of human glioma cells. The functional NY-
ESO-1 specific T cell recognition of decitabine-treated
glioma cells was comparable to the recognition of a
human melanoma cell line known to express high levels
of NY-ESO-1 [15,30]. Together, such data suggest that
adjuvant treatment with agents that modify DNA
methylation could potently synergize with targeted
immunotherapy for cancer.
NY-ESO-1 is a cancer/testis antigen that is considered
one of the most immunogenic members in the cancer
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Figure 5 Elevated cytokine secretion of NY-ESO-1 TCR-transduced PBMCs co-cultured with decitabine-treated T98G glioma cells.T 9 8
glioma cells were treated with or without decitabine and then co-cultured with NY-ESO-1 TCR-transduced T cells. Cell-free supernatants were
tested for cytokine secretion by IFN-g ELISA and cytometric bead array. A) Data from the IFN-g ELISA is depicted (p< 0.05). B) Concentrations of
Th1/Th2 cytokines IFN-g, TNF-a, and IL-5 (pg/mL) in co-cultured samples are depicted (***p < 0.001). Results shown are representative findings
from over 5 replicate experiments.
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Page 9 of 13testes antigen family. NY-ESO-1 is frequently expressed
in melanomas but not typically expressed in gliomas, as
are other members of the CTA family [10,13,14,34,35].
Our results showed that NY-ESO-1 was exclusively
expressed in decitabine-treated glioma cells, but not
expressed in untreated glioma cells or normal human
astrocytes (Figure 2). This is important because it sug-
gests that decitabine will up-regulate the relative
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Figure 6 Decitabine sensitizes glioma cells to an immune-mediated cell death via the Fas/FasL pathway. A) Decitabine-treated and
untreated T98G cells were stained with an anti-Fas antibody and analyzed by flow cytometric analysis. B) T98G cells were treated as described
previously and stained with an agonistic-Fas antibody (clone CH-11) to stimulate apoptosis for 24 hr. Results depict the average percentage of
late cell death in untreated alone, decitabine-treated alone, untreated with agonistic mAb, and decitabine-treated with agonistic mAb.
Decitabine-treated alone versus decitabine-treated with antibody (P = 0.0049). Untreated alone versus untreated with antibody (P = 0.0215).
Experiments were conducted in triplicate. C) Representative flow cytometric analysis of CD107A staining from NY-ESO-1 TCR transduced T cells
co-cultured with untreated T98G glioma cells, with or without the addition of an antagonistic-Fas antibody (clone ZB4) to block apoptosis (solid
filled, NY-ESO-1 specific T cells alone; solid line, NY-ESO-1 specific T cells co-cultured with untreated T98G glioma cells; dashed line, NY-ESO-1
specific T cells co-cultured with untreated T98G glioma cells with antagonistic-Fas antibody. NY-ESO-1 TCR transduced T cells were gated from
the CD8 population. D) Representative flow cytometric analysis of CD107A staining from NY-ESO-1 transduced T cells co-cultured with
decitabine-treated T98 glioma cells, with or without the addition of an antagonistic-Fas antibody (clone ZB4) to block apoptosis (solid filled, NY-
ESO-1 specific T cells alone; solid line, NY-ESO-1 specific T cells co-cultured with decitabine-treated T98G glioma cells; dashed line, NY-ESO-1
specific T cells co-cultured with decitabine-treated T98G glioma cells with antagonistic-Fas antibody. E) CBA was performed on cell-free
supernatant of samples from Figure 6C. Th1/Th2 cytokine concentrations IFN-g, TNF-a, and IL-5 (pg/mL) are depicted. (*p < 0.05; ** p < 0.01; NS,
not significant).
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Page 10 of 13expression of NY-ESO-1 only in tumor cells, therefore
alleviating concerns that decitabine treatment in vivo
could cause autoimmunity in patients undergoing NY-
ESO-1 T cell adoptive transfer. In support of this, Rob-
bins et al. demonstrated that the adoptive transfer of
NY-ESO-1 TCR-transduced T cells in patients with
metastatic melanoma and synovial cell sarcoma did not
result in any significant toxicity, suggesting that target-
ing CTAs using TCR-transgenic lymphocytes mediates
the regression of established tumors without damaging
normal tissues [15]. Thus, the effects of decitabine
appear to be tumor specific, inducing the expression of
multiple CTAs, such as NY-ESO-1, that can be poten-
tially used for immunotherapeutic targeting.
Recent studies have shown that immunotherapy with
antigen specific T cells can recognize tumor cells that
express the corresponding antigen, but the apoptotic sig-
naling system and survival pathways for such cells remain
dysfunctional [36-38]. Weller et al. suggested that the
endogenous apoptosis pathway can be induced in activated
human malignant gliomas [39]. The immunosensitization
of death receptor pathways in tumor cells is one mechan-
ism by which cancer immunotherapy death receptor acti-
vation by T cells is relatively selective to tumor cells
compared to non-malignant cells as previously described
[40,41]. However, evasion of apoptosis is a major charac-
teristic in most cancers, including glioblastomas. This can
be caused by the dysfunction in signaling downstream of
Fas and possibly other death receptors [38]. Fas/FasL is an
extrinsic death pathway that induces apoptosis upon tri-
merization of Fas after binding to FasL leading to the
recruitment of Fas-associated death domain (FADD). As
most glioblastoma cells are resistant to apoptosis induced
by Fas ligand, induction of apoptosis through this pathway
in gliomas will require sensitization by other means
[42,43]. Our results suggest that treatment with decitabine
could re-establish the functionality of this signaling system
and sensitize cells to an immune-mediated cell death by
the Fas/FasL pathway.
D e g r a n u l a t i o ni sa ne s s e n t i a ls t e pi nt h ep r o c e s so f
perforin-granzyme mediated killing and is critical for
rapid lytic function mediated by responding antigen-spe-
cific CD8
+ T cells. Lysosomal-associated membrane pro-
tein-1 (LAMP-1 or CD107A) is a sensitive marker of
cytotoxic CD8
+ T cell degranulation [33,44] that
increases dramatically upon T cell recognition of anti-
gen-expressing target cells. Our present results showed
that the expression of CD107A of decitabine-treated
glioma cells blocked with an antagonistic Fas mAb
decreased to almost 50% compared to decitabine-treated
cells. A previous study demonstrated that the use of an
antagonistic Fas mAb was specific to the Fas receptor
[45]. Our results strongly suggest that by blocking the
Fas/FasL pathway, there is a decrease in the efficacy of
targeting tumor cells by the cytotoxic CD8
+ T cells
when treated with decitabine. A recent study suggested
that rapid clearance of cancerous cells is most effective
through the use of both the Fas/Fas Ligand and Per-
forin/Granzyme pathways due to their complementary,
non-redundant killing mechanisms [36]. The present
data therefore support the role of decitabine in sensitiz-
ing glioma cells to apoptosis by the Fas/FasL pathway.
Conclusions
Our studies demonstrate that utilization of a demethy-
lating agent, such as decitabine, could induce the
expression of CTA such as NY-ESO-1 on glioma cells,
which in turn can act as effective target molecules for T
cell mediated therapy. Induction of this antigen, along
with an increased expression of MHC I, and upregula-
tion of proinflammatory cytokines may sensitize tumor
cells to tumor specific T cell-mediated cell injury. To
translate such findings into patients, we have already
planned a first-in-human Phase I clinical trial. In this
trial, patients with recurrent glioblastoma will receive
pre-operative decitabine (Dacogen
®), followed later by
the local adoptive transfer of NY-ESO-1 TCR-trans-
duced T lymphocytes through a Rickham reservoir
placed during surgery. Given the short half-life of deci-
tabine and long-lasting effects of the induced NY-ESO-1
expression, we anticipate that we will have a window of
opportunity to infuse such T cells without any drug sup-
pression. Overall, our studies indicate that decitabine
can aid in the effectiveness of cellular therapy with T
cells targeting NY-ESO and provide and eliminate con-
cerns that they will also target normal brain cells.
Additional material
Additional file 1: Treatment of human glioma with decitabine up-
regulates MHC I. Total RNA was isolated from U251 glioma cells treated
with decitabine or vehicle control and subjected to global gene
expression classification using Affymetrix human U133 Plus 2.0 microarray
chips. Data was analyzed with dChip microarray software.
Additional file 2: Flow cytometric characterization of NY-ESO-1 TCR-
transduced PBMC. Normal donor peripheral blood mononuclear cells
(PBMCs) were activated with OKT-3 at a concentration of 50 ng/mL for
two days and then harvested for transduction. PBMCs were transduced
with retroviral constructs encoding an HLA-A201-restricted NY-ESO-1 T
cell receptor, stained with multi-colored antibodies to CD3, CD8, and
TCRV b13.1, and finally analyzed by flow cytometry to estimate the
efficiency of transduction.
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